N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 性质
| 储存条件 | −20°C |
|---|---|
| 溶解度 | H2O:50 mg/mL |
| 形态 | 粉末 |
| 颜色 | 米白色 |
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 用途与合成方法
cGMP-dependent protein kinase (PKG);
ATP-sensitive K
+
channels
Dibutyryl-cGMP is able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.
When cells are co-incubated with Dibutyryl-cGMP (100 μM) stress fibre formation is prevented and cells acquired a stellate morphology in cerebellar astrocytes.
In cells treated with Dibutyryl-cGMP (100 μM, 2 h) the particulate fraction is nearly devoid of RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane association.
Using the scratchwound model, the size of the wound is significantly smaller in cells treated with Dibutyryl-cGMP after the wound indicating that dbcGMP accelerates wound closure.
Dibutyryl-cGMP (50-200 μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1 h after administration and last for plus 2 h.
| Animal Model: | Male Wistar rats (180- 250 g) injection with Prostaglandin E2 (PGE2) |
| Dosage: | 50 μg/paw, 75 μg/paw, 100 μg/paw and 200 μg/paw |
| Administration: | Subcutaneous injection |
| Result: | Antagonized the hyperalgesic effect of PGE2 (2 μg/paw), in a dose-dependent manner. |
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-130354 | 1 mg | 1590 | ||
| 2024-04-30 | HY-130354 | N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT | 51116-00-8 | 5mg | 3500 |
